This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Cell and gene therapies need ultra-cold storage and transport to work. As more of these treatments get approved, the companies keeping them frozen become critical—an opportunity most investors are missing.
While headline-grabbing biotech firms often face binary outcomes based on clinical trials, these behind-the-scenes companies earn revenue regardless of which therapies ultimately succeed—potentially offering smoother growth.
With cell and gene therapy approvals accelerating, demand for specialized manufacturing and logistics is surging. These companies are positioned to benefit from this momentum as the field transforms from experimental to mainstream.
We're focused on the companies behind the scenes making cell and gene therapy possible. Instead of betting on which treatments will succeed, we've selected the firms providing crucial infrastructure—from cryogenic storage to manufacturing components—that all therapies need regardless of clinical outcomes.
These stocks offer a different risk profile than traditional biotech investments. While they still operate in a fast-evolving sector, their services remain essential regardless of which specific therapies ultimately succeed, providing a more stable approach to capturing growth in advanced medicine.
Each company was selected because they provide irreplaceable services in the cell and gene therapy supply chain. As more advanced treatments receive regulatory approval, these firms face increasing demand for their specialized logistics, manufacturing capabilities, and quality control systems.
Concise summary and investor key takeaways for the Cell & Gene Therapy Logistics basket.
CYRX: $508.18M
BLFS: $1.33B
CCEL: $35.04M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+203.71%
On average, analysts expect assets in this group to grow 203.71% over the next year.
12 of 14 assets in this group are rated Buy by professional analysts.
